Moreover, the consistent superiority of rosuvastatin over atorvastatin in driving caspase-3 activation across both colorectal cancer cell lines reinforces its potential as the more efficacious agent for therapeutic exploitation in inflammation-associated colorectal malignancy. This evidence concerns the gene CASP3 and cancer.